The Rare Disease Action Forum (RDAF) advocates for a fair and rapid access to high-quality treatment for patients with rare diseases in Switzerland.

    3 Oct, 2022

    In line with this concern, the RDAF would like to draw attention to the fact that the planned revision of the Health Insurance Ordinance (KVV), contrary to its stated objective, threatens patients’ access to treatment.

    Read our media release here.

    Continue reading

    Joint statement on the KVV/OAMal and KLV/OPAS revision

    The RDAF co-signed a joint statement with other stakeholders on the revision of the Health Insurance Ordinance (KVV/OAMal) and Health Benefits Ordinance (KLV/OPAS). The statement highlights the potential negative impacts of the revision, including the following: -...

    RDAF position statement on KVV/KLV revision

    The Rare Disease Action Forum has published a position paper in relation to the consultation organized by the Federal Office of Public Health on the revision of the Health Insurance Ordinance (KVV/OAMal) and the Health Benefits Ordinance (KLV/OPAS). In its position...